DDX41 and acute myeloid leukemia: A recent study by Duployez et al. showed prolonged survival in DDX41 germline mutant AML patients, with a good response to intensive chemotherapy in intermediate or high-risk patients with AML, in a large cohort study using five prospective clinical trials of 191 newly diagnosed DDX41 mutant AML patients [57].